Celano Michael purchased $50K of LRMR

Celano Michael (Chief Financial Officer) purchased 18,460 shares of Larimar Therapeutics, Inc. (LRMR) at $2.71 on 2026-11-11.

Original reporting
SEC EDGAR · Celano Michael
Published Nov 12, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Bullish
high confidence
Mentioned
$LRMR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRBullishLow
01

Why it matters

The transaction adds a modest positive signal but is unlikely to cause significant price movement.

02

Market read

Primary insider purchase news; low trading relevance but useful for monitoring insider sentiment.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed could be the real driver behind the purchase.

Relevance 4/10Novelty 4/10Timing: after market today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CFO's purchase.

Company-level read

Ticker impact

$LRMRBullishHigh confidence
Context

CFO Celano Michael purchased 18,460 shares of Larimar Therapeutics at $2.7081 each, totaling $49,992.

Expected impact

likely modest upward pressure as market interprets the purchase positively

Evidence & confidence

Form 4 is a primary source; the purchase is small but signals insider confidence, which can influence short-term sentiment.

Market effects

May slightly boost sentiment in the biotech sector as insider buying is viewed positively.

Limited to U.S. markets where LRMR trades; no broader regional effect.

Minimal global impact; relevance confined to investors tracking LRMR.

Counterpoint

The purchase is too small to move the stock and could be routine portfolio rebalancing.

Key entities

  • Larimar Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Celano Michael

    Chief Financial Officer of Larimar Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.